A composition for controlling or preventing progression of glaucoma comprises a material that reduces or inhibits production of a TGF-beta isoform or a chemokine or cytokine that stimulates expression of a TGF-beta isoform. The material can comprise a dissociated glucocorticoid receptor agonist ("DIGRA"), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can further comprise an antagonist to TGF-beta. It is administered to a patient who has undergone glaucoma filtration surgery to ensure a functioning filtering bleb following such surgery.
